Perspective maps cancer dark proteome and gaps in therapeutic development

A Perspective in Nature Reviews Cancer examines the cancer “dark proteome”: unconventional, poorly characterized proteins and peptides arising from non-canonical open reading frames, repeat elements, circular RNAs, mistranslation, proteasomal processing and stress-induced translation. The article surveys current knowledge and research priorities rather than reporting a clinical trial or patient cohort.

Over the past decade, researchers have identified diverse classes of dark proteins, each containing thousands of members. Tools including ribosome profiling (Ribo-seq), immunopeptidomics, mass spectrometry, CRISPR screens and saturation mutagenesis are helping map these molecules and investigate their functions. Individual dark proteins may act as oncogenes, tumour suppressors, signalling regulators, immune antigens or cancer-specific genetic dependencies.

The Perspective highlights dark proteome-derived antigens as potential targets for vaccines, T-cell receptor-engineered T cells, CAR-T approaches and bispecific T-cell engagers. However, fundamental gaps remain in understanding their regulation, contribution to cancer phenotypes, antigenicity and suitability for clinical-grade therapies. The supplied preview provides no clinical efficacy or safety outcomes; these potential applications should therefore be understood as research directions, not established treatment options.